Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to ...

Diabetes and obesity disproportionately impact Black people, yet they are facing greater challenges gaining access to GLP-1 ...

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in ...

Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's. Both stocks could be winners for ...

A diabetes medication in short supply for the last two years often was prescribed to people who didn't have the disease, and prescribing rates varied dramatically across the country, new data shows.

As the popularity of appetite-suppressing drugs like Ozempic and Wegovy continues to skyrocket, one of America's chief snack food overlords is readying himself — and his company's delicious ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk expects demand for its weight loss drugs to continue to outstrip supply despite expanding ...

Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and ...

Is the fervor over Ozempic just a passing fad? It doesn't appear to be the case after Novo Nordisk (NYSE: NVO) announced its results for the first nine months of 2023 on Thursday morning.

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in profits on the back of surging demand for the drugs. Net profits were 39 ...